MX2023002350A - Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. - Google Patents

Composiciones y metodos para mejorar enfermedades y trastornos neurologicos.

Info

Publication number
MX2023002350A
MX2023002350A MX2023002350A MX2023002350A MX2023002350A MX 2023002350 A MX2023002350 A MX 2023002350A MX 2023002350 A MX2023002350 A MX 2023002350A MX 2023002350 A MX2023002350 A MX 2023002350A MX 2023002350 A MX2023002350 A MX 2023002350A
Authority
MX
Mexico
Prior art keywords
compositions
methods
disorders
neurological diseases
patient
Prior art date
Application number
MX2023002350A
Other languages
English (en)
Inventor
Gabriel Vargas
Wei Chen
Anthony P Ford
Renee S Martin
Original Assignee
Curasen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curasen Therapeutics Inc filed Critical Curasen Therapeutics Inc
Publication of MX2023002350A publication Critical patent/MX2023002350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/501—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the head, e.g. neuroimaging or craniography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Hospice & Palliative Care (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Dentistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En varios aspectos y formas de modalidad se proporcionan composiciones y métodos para identificar pacientes que necesitan mejorar la cognición y/o tratar una enfermedad neurodegenerativa en un paciente y tratar a dicho paciente. Más específicamente, la divulgación en algunas formas de modalidad incluye la administración de un agonista ß-AR (tal como un agente ß) y un ß-bloqueante de acción periférica (PABRA) a un paciente que lo necesite.
MX2023002350A 2020-09-01 2021-08-31 Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. MX2023002350A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073353P 2020-09-01 2020-09-01
US202163212077P 2021-06-17 2021-06-17
PCT/US2021/048540 WO2022051305A1 (en) 2020-09-01 2021-08-31 Compositions and methods for improving neurological diseases and disorders

Publications (1)

Publication Number Publication Date
MX2023002350A true MX2023002350A (es) 2023-04-26

Family

ID=80491939

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002350A MX2023002350A (es) 2020-09-01 2021-08-31 Composiciones y metodos para mejorar enfermedades y trastornos neurologicos.

Country Status (8)

Country Link
US (1) US20230263749A1 (es)
EP (1) EP4208159A1 (es)
JP (1) JP2023541379A (es)
KR (1) KR20230107211A (es)
AU (1) AU2021337583A1 (es)
CA (1) CA3189243A1 (es)
MX (1) MX2023002350A (es)
WO (1) WO2022051305A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240146384A1 (en) 2021-03-03 2024-05-02 Lenovo (Singapore) Pte. Ltd. Beam failure detection using shared reference signals

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
US9320724B2 (en) * 2013-02-13 2016-04-26 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
US20210251559A1 (en) * 2018-06-14 2021-08-19 Curasen Therapeutics, Inc. Methods for diagnosing, monitoring and treating neurological diseases and disorders
US11040944B2 (en) * 2019-03-27 2021-06-22 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
JP2022553371A (ja) * 2019-10-25 2022-12-22 キュラセン セラピューティクス インコーポレイテッド α１Ａ－ＡＲ部分アゴニストを用いて神経障害を治療するための方法
WO2021127210A1 (en) * 2019-12-18 2021-06-24 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders

Also Published As

Publication number Publication date
CA3189243A1 (en) 2022-03-10
AU2021337583A9 (en) 2024-06-27
WO2022051305A1 (en) 2022-03-10
AU2021337583A1 (en) 2023-05-04
JP2023541379A (ja) 2023-10-02
US20230263749A1 (en) 2023-08-24
EP4208159A1 (en) 2023-07-12
KR20230107211A (ko) 2023-07-14

Similar Documents

Publication Publication Date Title
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR0312851A (pt) Composto, composição farmacêutica, e, métodos para tratar ou previnir câncer, degeneração macular de tipo úmido ou artrite reumatóide, vascularização anÈmala, nìveis de cobre em excesso em um paciente, obesidade e doença neurodegenerativa em um paciente
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
MX2021015352A (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal.
CR20220036A (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
EP4233913A3 (en) Improved bromocriptine formulations
WO2019195761A3 (en) Pharmacological agents for treating ocular diseases
MX2022012692A (es) Composiciones que comprenden nanoparticulas, metodo de elaboracion y usos de las mismas.
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
MX2021011230A (es) Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
MX2022013650A (es) Imidazopirimidinas como moduladores de il-17.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
NZ767378A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2023014484A (es) Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.
MX2023002350A (es) Composiciones y metodos para mejorar enfermedades y trastornos neurologicos.
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
MX2021012579A (es) Composiciones farmaceuticas a base de peptidos de colageno y dispositivos y metodos de produccion y uso de los mismos.